Friday February 24th 2017: AstraZeneca PLC, AZN is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in United Kingdom, AstraZeneca PLC, AZN has a market cap of 85.69 B. Since its IPO date on the 5/17/1993, AstraZeneca PLC, AZN performance year to date is 23.98%. Today AstraZeneca PLC, AZN has gained -0.41%, with a current price of 33.73.
Ownership of the company is 0.50% for insider ownership while institutional ownership is 14.90%. The management of the company have seen the company have a payout ratio of 33.60%. Return of assets are at 5.40%, with return on investment at 15.00%.
In terms of debt levels and profit levels, AstraZeneca PLC, AZN is seeing a long-term debt/equity of 1.12. While Total debt/equity is 1.34. With a profit margin of 15.20%, this is combined with a gross margin of 82.70%, and operating margin of 21.40%. AstraZeneca PLC ability to meet debt levels, with a current ratio of 0.8, while the quick ratio is 0.6.
For the last year AstraZeneca PLC, AZN has seen a EPS growth of 23.80%. A performance for the year of 11.63%. The 52-week high is -5.25%, and the 52-week low is 32.02%. The average volume for AstraZeneca PLC, AZN is 45976.
With a target price of 34.12, can AstraZeneca PLC, AZN reach this target? Looking at the value indicators of AstraZeneca PLC, AZN. AstraZeneca PLC has a P/E of 25.29 and a forward P/E of 17.73. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.47. AstraZeneca PLC also has a P/S and a P/B of 3.84 and 6.6 respectively. For P/cash, AstraZeneca PLC has a value of 23.42, while it is *TBA for P/free cash flow.
At the current price of 33.73, AstraZeneca PLC has a dividend yield of 5.61%. We see a return on equity of 24.90%.
Looking more long-term AstraZeneca PLC, is projected to get an EPS growth for the next five years of 7.30%. In the short-term an EPS growth of 2.96% in the next year is forecasted. This is after a EPS growth of 23.80% for this year and for the last five years a -17.60% growth has been seen.